Clinical Trial Update: An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluating safety and tolerability of BEMA Buprenorphine NX in individuals with opioid use disorder has completed. Results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• BEMA Buprenorphine NX (buprenorphine)

Snippet

Sponsor: BioDelivery Sciences International | Conditions: Opioid Dependence | Phase 2 | Status: COMPLETED | Results posted: 2017-04-04